Kyowa Hakko Kirin Logo
JP3256000005
858523
4151.T

Kyowa Hakko Kirin

Kurser indlæses...

Prognose

Vi har ingen analytikerdata for denne virksomhed.

Diskussioner i communityet

Der er endnu ingen diskussion om dette aktiv.

Start diskussion

  • Kyowa Kirin stock plunges after concerns over US price pressure

    Kyowa Kirin’s share fell 11.1% today to ¥2,390 after market participants reassessed the impact of a US pricing agreement in the Medicaid program. Investors fear that expanded rebate requirements could hit sales and Kyowa Kirin’s North America business — a key growth driver — hard. Additional selling pressure came from mostly negative analyst ratings and a weaker Asian market environment; Kyowa Kirin was the biggest loser on the Nikkei 225. » Mere på de.investing.com


  • Kyowa Kirin reaches price agreement with US government, stock rises

    Kyowa Kirin’s share rose 2.0% to ¥2,681 after the company became part of a price agreement with the US government. Kyowa Kirin is one of nine drugmakers that agreed to lower prices for medicines in the US Medicaid program. The company had earlier reported positive half‑year results and expressed optimism; the stock therefore outperformed the weaker Nikkei 225. » Mere på de.investing.com


  • Kyowa Hakko Kogyo pays dividend of 62.00 JPY for 2025

    At the annual general meeting on 19 March 2026, Kyowa Hakko Kogyo approved a dividend for 2025 of 62.00 JPY, an increase of 6.90% year on year. The total payout amounts to 30.88 billion JPY and the dividend yield is 2.45%; the share is now trading ex‑dividend. Over three years the share price fell by 17.27%, and the real return including dividends is -17.01%. FactSet analysts expect a dividend of 67.82 JPY for 2026 (estimated yield 2.89%). » Mere på finanzen.net


  • Kyowa Kirin takes back Rocatinlimab program from Amgen and plans filings for first half of 2026

    Kyowa Kirin has regained control of the global development and commercialization program for Rocatinlimab from Amgen and will submit regulatory applications first in the US and then in Japan. Amgen is exiting the collaboration as part of its portfolio prioritization but will remain the drug substance manufacturer and support an orderly transition. Rocatinlimab showed convincing efficacy in two phase‑III studies involving nearly 1,500 adults with moderate to severe atopic dermatitis; the phase‑III program includes more than 3,300 patients and various populations. The safety profile was consistent, with common, mostly mild adverse events; additional data will be presented at medical congresses. » Mere på finanzen.net


  • Kyowa Kirin: Abdul Mullick will be CEO in March 2026 and first non-Japanese company head

    The board of Kyowa Kirin appointed Abdul Mullick, currently president and COO, effective after the annual general meeting in March 2026 as president and chief executive officer. Masashi Miyamoto will remain chairman; the change follows the previously introduced dual CEO/COO structure and is intended to make leadership more agile. Mullick, at the company since 2017 and previously in senior roles at Sanofi and Novartis, will continue to work from the global headquarters in Tokyo. » Mere på de.investing.com

I 2026 har Kyowa Hakko Kirin allerede udloddet 0,36 € i udbytte. Den seneste udlodning fandt sted i september.

Virksomhedstal

I det seneste kvartal havde Kyowa Hakko Kirin en omsætning på 687,27 mio. € og et nettoresultat på 119,28 mio. €
(EUR) september 2026
YoY
Omsætning 687,27 mio. 0,94 %
Bruttofortjeneste 498,77 mio. 5,73 %
Nettoresultat 119,28 mio. 25,46 %
EBITDA 200,66 mio. 2,68 %

Fundamentale data

Nøgletal Værdi
Markedsværdi
7,75 mia. €
Antal aktier
523,59 mio.
Højeste/laveste i 52 uger
16,34 € - 3,81 €
Udbytteafkast
2,47 %
Udbytte TTM
0,36 €
Beta
0,42
P/E (PE Ratio)
15,72
PEG (PEG Ratio)
0,12
K/I (PB Ratio)
1,49
P/S (PS Ratio)
2,54

Virksomhedsprofil

Kyowa Kirin Co., Ltd. fremstiller og markedsfører lægemidler, der fokuserer på de terapeutiske områder onkologi, nefrologi, centralnervesystemet og immunologi på verdensplan. Virksomhedens produkter omfatter ABSTRAL, en sublingual formulering af fentanyl, der anvendes til behandling af gennembrudssmerter hos kræftpatienter; ALLELOCK, et antihistamin til patienter med forskellige typer allergi; CONIEL, en calciumkanalblokker til hypertension og angina pectoris; Crysvita, et rekombinant humant monoklonalt IgG1-antistof mod det fosfaturiske hormon fibroblastvækstfaktor 23; ESPO, et glykoprotein og humant erythropoietin; NESP, et erythropoesestimulerende middel; og GRAN, en human kolonistimulerende faktor. Virksomheden udvikler desuden G-LASTA/Peglasta/Neulasta til kemoterapi-induceret febril neutropeni; LEUNASE til akut lymfoblastisk leukæmi; LUMICEF, en biologisk behandling af moderat til svær plaque-psoriasis; Moventig, en mu-opioidreceptorantagonist til behandling af opioidinduceret obstipation; Nouriast/ Nourianz, en adenosinreceptorantagonist til Parkinsons sygdom; og ORKEDIA, et oralt calcimimetikum. Derudover tilbyder virksomheden PecFent, en nasalt administreret spray; POTELIGEO, et humaniseret monoklonalt antistof mod CC-chemokinreceptor 4; REGPARA til behandling af sekundær hyperparathyreoidisme; Romiplate/Nplate, et genetisk rekombinant protein til trombocytproduktion via trombopoietinreceptorer; og SANCUSO til behandling af kvalme og opkastning. Kyowa Kirin Co., Ltd. har en aftale med Amgen Inc. om i fællesskab at udvikle og kommercialisere KHK4083, et fase 3-klart anti-OX40 fuldt humant monoklonalt antistof til behandling af atopisk dermatitis. Virksomheden var tidligere kendt som Kyowa Hakko Kirin Co., Ltd. og skiftede navn til Kyowa Kirin Co., Ltd. i juni 2019. Virksomheden blev stiftet i 1949 og har hovedsæde i Tokyo, Japan. Kyowa Kirin Co., Ltd. er et datterselskab af Kirin Holdings Company, Limited.

Navn
Kyowa Hakko Kirin
CEO
Abdul Hafeez Mullick
Hjemsted Tokyo, ty
Japan
Websted
Sektor
Sundhed
Branche
Lægemidler
Børsnotering
04.01.2000
Medarbejdere 5.161

Tickersymboler

Børs Symbol
Japan Exchange Group
4151.T
Pnk
KYKOF
Frankfurt
KY4.F
Düsseldorf
KY4.DU
München
KY4.MU
🍪

Parqet  bruger cookies. Læs mere